Stavros Athanasopoulos

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study

V. Libri, L. Huson, R. Festenstein, 2014, The Lancet.

Diabetes and COVID-19; A Bidirectional Interplay

M. Dimopoulos, I. Kalomenidis, V. Lambadiari, 2022, Frontiers in Endocrinology.

Glycemia is associated with subclinical atherosclerosis through renal function in nondiabetic apparently healthy adults: a mediation analysis

K. Stamatelopoulos, A. Mitrakou, G. Georgiopoulos, 2023, Hypertension Research.

A wearable motion capture suit and machine learning predict disease progression in Friedreich’s ataxia

V. Ricotti, R. Festenstein, T. Voit, 2023, Nature Medicine.

Kinematic body sensor networks and behaviourmetrics for objective efficacy measurements in neurodegenerative disease drug trials

Constantinos Gavriel, A. Aldo Faisal, Andreas A. C. Thomik, 2015, 2015 IEEE 12th International Conference on Wearable and Implantable Body Sensor Networks (BSN).

Towards neurobehavioral biomarkers for longitudinal monitoring of neurodegeneration with wearable body sensor networks

Constantinos Gavriel, A. Aldo Faisal, Andreas A. C. Thomik, 2015, 2015 7th International IEEE/EMBS Conference on Neural Engineering (NER).

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study

V. Libri, L. Huson, R. Festenstein, 2014, The Lancet.